GLP-1 receptor agonists reduce cardiovascular events in people without obesity or established cardiovascular disease.
- Current status
- Insufficient evidenceEvidence stable · Cardiovascular
- Why
- No outcome trial has enrolled such a population. REWIND included T2D participants without prior CVD (benefit similar), but all had diabetes. The umbrella review found no significant MACE benefit in those without baseline CVD.
- What would change it
- A randomized primary-prevention outcome trial in adults without obesity or diabetes.
- Linked studies
- 2 · 1 contradicts · 1 mixed
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Contradicts (1)
- Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
No significant MACE/MI reduction among participants without CVD at baseline.
Mixed (1)
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialRandomized trial · 2019 · Study tier 1 · Different population · Benefit · Industry funded
REWIND: benefit in T2D with and without prior CVD (all had diabetes).
02History
How this assessment has changed
- Insufficient evidenceSep 13, 2026 · Evidence stable
initial curated status